Physician profile
Mark Granata
NPI 1689616534
$879.24
in general payments reported to CMS, 2019-2025
10 companies · $51.92 in 2025
The $51.92 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $225 · 2021: $50.79 · 2022: $209 · 2023: $139 · 2024: $87.47 · 2025: $51.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $299.08 | 2019-2025 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $256.93 | 2019-2023 | Puraply |
| Musculoskeletal Transplant Foundation INC. | $185.04 | 2020 | |
| Urgo Medical North America, LLC | $33.65 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Kci USA, INC. | $22.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.30 | 2024 | Nuzyra |
| Solventum Corporation | $17.69 | 2025 | Activ.A.C. |
| Celularity INC. | $17.00 | 2019 | |
| Integra Lifesciences Corporation | $15.39 | 2022 | |
| Merck Sharp & Dohme LLC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Granata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.